Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
As a new crypto investor, it's crucial to know what to watch out for to avoid costly mistakes. Equip yourself with knowledge to navigate the market safely.
27,825 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A new era of autonomous AI agents could turbocharge voice tech leaders. Learn how agentic will supercharge soundhound...
Entrepreneurship powered America’s rise, and Steve Case argues we must expand that engine nationwide to guard the cou...
Global regulators are tightening the rules around AI financing as investment soars, signaling potential shifts in fun...
The Federal Communications Commission announced an enforcement action against The View over possible equal-time viola...
Howmet Aerospace and GE Vernova push higher in 2026 as AI data centers and power upgrades drive engine and turbine or...
Apple and Intel are reportedly exploring a U.S.-based chip supply and manufacturing pact. The talks, if they advance,...
An insider at Mirion Technologies reduced his stake by roughly $165,000 in a May 2026 move. This article explains how...
A stock rally like sandisk stock 770% this year draws loud skeptics and eager bulls alike. This guide breaks down wha...
AI data centers are sparking a sweeping power expansion in the U.S. Three utility ETFs offer distinct routes to ride ...
Tesla beat market expectations with stronger-than-forecast Q4 results, sending shares higher as investors weigh the c...
Oracle stunned traders with a solid earnings beat and optimistic long-term guidance, fueling a surge in after-hours a...